Bioresorbable Stent Company, Arterial Remodeling Technologies, Raises EUR 5.5 ($7.8) Million in New Venture Financing Round from Investors Matignon Technologies and SGAM Alternative Investments

PARIS--(BUSINESS WIRE)--Arterial Remodeling Technologies (“ART”) announced today that it has closed on a new venture financing round of €5.5 ($7.8) million from investors Matignon Technologies and SGAM Alternative Investments (using existing funds as well as a new fund dedicated to cardiovascular investments: “SEFTI”). Proceeds will be used to pursue CE Mark clearance for the Company’s first product, a bioresorbable stent that dismantles in vivo over an optimized time horizon.